Back to Search
Start Over
Of patents and patent disputes - The TNFα patent files. Part 2: Enbrel, Remicade, Cimzia and Simponi.
- Source :
-
Human antibodies [Hum Antibodies] 2018 Feb 05; Vol. 26 (2), pp. 49-61. - Publication Year :
- 2018
-
Abstract
- This article is the second part of a trilogy that discusses IP issues related to anti-Tumor Necrosis factor α (TNFα) biologics. TNFα is the world's most valuable target, with accumulated sales of TNFα biologics of 34 bn USD in 2014. While in the first part of this trilogy, Humira was discussed, this second parts discusses the patent strategies of Enbrel, Remicade, Cimzia and Simponi.
- Subjects :
- Adalimumab therapeutic use
Antibodies, Monoclonal economics
Antibodies, Monoclonal therapeutic use
Antirheumatic Agents supply & distribution
Antirheumatic Agents therapeutic use
Arthritis, Rheumatoid economics
Arthritis, Rheumatoid genetics
Arthritis, Rheumatoid immunology
Biosimilar Pharmaceuticals supply & distribution
Biosimilar Pharmaceuticals therapeutic use
Certolizumab Pegol economics
Certolizumab Pegol therapeutic use
Dissent and Disputes legislation & jurisprudence
Drug Administration Schedule
Drug Dosage Calculations
Etanercept economics
Etanercept therapeutic use
Gene Expression Regulation
Humans
Infliximab economics
Infliximab therapeutic use
Patents as Topic
Tumor Necrosis Factor-alpha genetics
Tumor Necrosis Factor-alpha immunology
Adalimumab economics
Antirheumatic Agents economics
Arthritis, Rheumatoid drug therapy
Biosimilar Pharmaceuticals economics
Dissent and Disputes economics
Tumor Necrosis Factor-alpha antagonists & inhibitors
Subjects
Details
- Language :
- English
- ISSN :
- 1875-869X
- Volume :
- 26
- Issue :
- 2
- Database :
- MEDLINE
- Journal :
- Human antibodies
- Publication Type :
- Academic Journal
- Accession number :
- 29439320
- Full Text :
- https://doi.org/10.3233/HAB-170321